Homepage>Company>Media>Pharma News>2020>TAZVERIK™ (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma - First and Only EZH2 Inhibitor Approved by the U.S. FDA
TAZVERIK™ (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma - First and Only EZH2 Inhibitor Approved by the U.S. FDA